• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    AN2 Therapeutics, Inc. - Common Stock (NQ: ANTX )

    2.130 -0.020 (-0.93%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 29,455
    Open 2.150
    Bid (Size) 2.060 (100)
    Ask (Size) 2.270 (21)
    Prev. Close 2.150
    Today's Range 2.110 - 2.160
    52wk Range 1.910 - 22.22
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024
    ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -89.28%
    -89.28%
    1 Month
    +1.43%
    +1.43%
    3 Month
    -43.35%
    -43.35%
    6 Month
    -89.28%
    -89.28%
    1 Year
    -74.52%
    -74.52%

    More News

    Read More
    AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023
    Via InvestorPlace
    AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    Nasdaq Edges Lower; ContextLogic Shares Surge
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    US Stocks Mixed; Trimble Issues Weak Outlook
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Is Infectious Disease-Focused AN2 Therapeutics Stock Sinking Today?
    Via Benzinga
    Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
    From AN2 Therapeutics, Inc.
    Via Business Wire
    AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
    From AN2 Therapeutics, Inc.
    Via Business Wire
    AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    AN2 Therapeutics to Present at Upcoming Investor Conferences
    From AN2 Therapeutics, Inc.
    Via Business Wire
    AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
    From AN2 Therapeutics, Inc.
    Via Business Wire
    AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
    From AN2 Therapeutics, Inc.
    Via Business Wire
    AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
    From AN2 Therapeutics, Inc.
    Via Business Wire
    AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
    From AN2 Therapeutics, Inc.
    Via Business Wire
    Top 5 Health Care Stocks That May Fall Off A Cliff
    Via Benzinga
    $16M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.